Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Sold by Shaker Investments LLC OH

Shaker Investments LLC OH reduced its position in Medpace Holdings, Inc. (NASDAQ:MEDP) by 92.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 755 shares of the company’s stock after selling 9,008 shares during the period. Shaker Investments LLC OH’s holdings in Medpace were worth $251,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in MEDP. R Squared Ltd purchased a new stake in shares of Medpace during the 4th quarter worth about $30,000. Stone House Investment Management LLC acquired a new position in Medpace in the 3rd quarter worth about $33,000. Ashton Thomas Securities LLC purchased a new position in Medpace during the third quarter worth approximately $37,000. Capital Performance Advisors LLP acquired a new stake in Medpace in the third quarter valued at approximately $46,000. Finally, True Wealth Design LLC increased its position in shares of Medpace by 16,800.0% in the third quarter. True Wealth Design LLC now owns 169 shares of the company’s stock valued at $56,000 after buying an additional 168 shares in the last quarter. Institutional investors and hedge funds own 77.98% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the stock. Robert W. Baird lifted their price target on shares of Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a research note on Monday, January 27th. Truist Financial dropped their target price on shares of Medpace from $415.00 to $397.00 and set a “hold” rating on the stock in a research report on Monday, October 14th. TD Cowen decreased their price target on shares of Medpace from $413.00 to $372.00 and set a “buy” rating on the stock in a research note on Wednesday, October 23rd. Redburn Atlantic started coverage on Medpace in a research note on Monday, October 14th. They set a “buy” rating and a $404.00 price objective for the company. Finally, Baird R W downgraded Medpace from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 23rd. Seven analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $381.44.

Medpace Stock Performance

NASDAQ MEDP opened at $354.51 on Tuesday. Medpace Holdings, Inc. has a fifty-two week low of $302.01 and a fifty-two week high of $459.77. The firm has a market capitalization of $11.02 billion, a P/E ratio of 31.04, a price-to-earnings-growth ratio of 1.85 and a beta of 1.36. The stock’s fifty day moving average is $343.88 and its two-hundred day moving average is $349.52.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Monday, February 10th. The company reported $3.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.96 by $0.71. Medpace had a net margin of 17.66% and a return on equity of 50.87%. As a group, sell-side analysts forecast that Medpace Holdings, Inc. will post 11.93 EPS for the current year.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.